Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients

Table 5

Comparison of laboratory and clinical data of truly poor mobilizers (defined as not achieving ≥2 × 10⁶ CD34+ cells/kg with first mobilization) during their 1st and 2nd mobilizations.

	1st mobilization (G-CSF alone)	2nd mobilization (G-CSF + Plerixafor)
Median number of apheresis days (range)	3 (2–5)	2 (1–5)
Median CD34+ ×10^6/kg collected (range)	0.77 (0.24–1.98)	2.89 (0.72–22.5)*
Median WBC on 1st day of apheresis, ×10^3/mm^3 (range)	30.6 (5–59.6)	52.8 (21.2–94.6)*
Median PLT count on 1st day of apheresis, ×10^3/mm^3 (range)	114 (39–365)	132 (44–265)

^†The number of poor mobilizers was 13, 4 multiple myeloma (MM) and 9 lymphoma patients. One MM patient died before transplant, and two patients had tandem transplants. Median transplant cell dose for these patients was 3.68 × 10⁶ CD34+/kg (range, 1.92–5.01).
*Significantly different with P ≤ 0.025.